Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

Autor: Chris M.G. Thomas, María Moreno, Silvia von Mensdorff-Pouilly, Fred C.G.J. Sweep, René H.M. Verheijen, Leon F.A.G. Massuger, Angèle L.M. Oei
Přispěvatelé: Obstetrics and gynaecology, CCA - Disease profiling
Rok vydání: 2008
Předmět:
Adult
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Aetiology
screening and detection [ONCOL 5]
Immunoglobulin E
Gastroenterology
Disease-Free Survival
law.invention
Randomized controlled trial
Translational research [ONCOL 3]
law
Internal medicine
medicine
Humans
Yttrium Radioisotopes
skin and connective tissue diseases
neoplasms
MUC1
Molecular diagnosis
prognosis and monitoring [UMCN 1.2]
Aged
Neoplasm Staging
Ovarian Neoplasms
Hereditary cancer and cancer-related syndromes [ONCOL 1]
biology
Endocrinology and reproduction [UMCN 5.2]
business.industry
Immunotoxins
Standard treatment
Hormonal regulation [IGMD 6]
Mucin-1
Antibodies
Monoclonal
Cancer
Immunotherapy
gene therapy and transplantation [UMCN 1.4]
Immunotherapy
Middle Aged
medicine.disease
Clinical trial
Oncology
Immunoglobulin G
Immunology
biology.protein
Female
Antibody
business
Zdroj: International Journal of Cancer, 123, 1848-53
International Journal of Cancer, 123, 8, pp. 1848-53
Oei, A L, Moreno, M, Verheijen, R H M, Sweep, F C, Thomas, C M, Massuger, L F & von Mensdorff-Pouilly, S 2008, ' Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer ', International Journal of Cancer, vol. 123, no. 8, pp. 1848-1853 . https://doi.org/10.1002/ijc.23725
International Journal of Cancer, 123(8), 1848-1853. Wiley-Liss Inc.
ISSN: 1097-0215
0020-7136
Popis: Contains fulltext : 69735.pdf (Publisher’s version ) (Closed access) We investigated whether epithelial ovarian cancer patients participating in a randomized phase III trial comparing single intraperitoneal (IP) administration of yttrium-90-labeled murine HMFG1 ((90)Y-muHMFG1) plus standard treatment (AT) vs. standard treatment (ST) alone developed IgG ab to MUC1 that had an impact on disease outcome. Serial serum samples from 208 patients in the AT and 199 patients in the ST arm were tested for IgG ab to MUC1 (anti-MUC1 IgG). Anti-MUC1 IgG at weeks 4, 8 and 12 ranked higher in the AT than in the ST arm (p < 0.001). The median (range) area under the curve (AUC) of anti-MUC1 IgG for weeks 1 to 12 was 5.53 (1.51-39.51) and 3.92 (1.17-68.74) for the AT and ST arm, respectively (p < 0.001). An anti-MUC1 IgG AUC > 13 was associated with a benefit in overall survival (OS) and disease-free survival (DFS) in the AT arm in univariate (p = 0.043 and 0.036, respectively), but not in multivariate analysis (Cox proportional hazards regression model). Kaplan-Meier analysis showed a benefit in OS and DFS in patients with an anti-MUC1 IgG AUC > 13 in the AT arm (p = 0.043 and 0.036, respectively), but not in the ST arm. A single IP injection with muHMFG1 did not lead to a survival benefit in the randomized trial, but it induced ab to MUC1 that were associated with an improved disease outcome in patients with highest levels of anti-MUC1 IgG. Immunotherapy against MUC1 could be effective in the treatment of epithelial ovarian cancer.
Databáze: OpenAIRE
Externí odkaz: